Europe Life Sciences Weekly Signal #39 Acquiring Is Not Operating
Week of 25–31 May 2026
Life sciences organisations have never had more ways to acquire capability.
They can buy pipelines, license products, enter new geographies through partnerships, deploy increasingly sophisticated AI platforms, or secure access to new markets through regulatory approvals. Capital remains available for the right assets, technology has become easier to access, and partnerships can often deliver capabilities that once required years to build internally.
Yet many organisations continue to discover the same uncomfortable reality. Acquiring capability and operating capability are not the same thing.
That distinction surfaced repeatedly this week.
Eli Lilly assembled a vaccine portfolio worth up to $3.8 billion through three acquisitions. Merz Therapeutics expanded its Parkinson’s franchise into China through a licensing agreement. Former Palantir executives launched a new AI platform designed to support drug development. Sanofi advanced a rare disease programme into a more complex patient population. Cornerstone Robotics secured MDR CE Mark approval for its surgical platform. EUDAMED crossed the line from future requirement to operational reality across Europe.
At first glance, these appear to be unrelated stories.
Viewed through an operating-model lens, they are variations of the same one.
Commercial Moves
The clearest commercial signal this week came from two very different transactions.
Eli Lilly’s acquisition of three vaccine companies.
Eli Lilly’s acquisition of three vaccine companies was widely reported as a portfolio move, but the more interesting question is whether Lilly is rebuilding a vaccine capability or simply acquiring vaccine assets. Vaccine businesses operate according to different commercial rules than treatment-focused pharmaceutical franchises. Recommendation bodies, public-health infrastructure, procurement pathways, and prevention-focused patient journeys all require capabilities that cannot be acquired in a transaction.
What makes Lilly’s move notable is that the company appears to understand this distinction. The recruitment of former FDA vaccine leader Peter Marks preceded the acquisitions, suggesting that leadership capability was established before portfolio expansion. The acquisitions answer the question of what Lilly wants to own. The next few years will determine whether it can build the organisational capability required to commercialise those assets successfully.
Merz Therapeutics chooses access to China via partnership
Merz Therapeutics faces a different challenge but arrived at a similar conclusion. Its agreement with Jiangxi Kvvit Pharmaceutical covering Inbrija across mainland China, Hong Kong and Macao is less about geography than capability. China market access increasingly depends on local evidence generation, regulatory execution, reimbursement navigation, and commercial infrastructure. Rather than attempting to build those capabilities internally, Merz has chosen to access them through partnership.
Both stories point to the same conclusion. Growth increasingly depends not on asset ownership alone, but on understanding which capabilities should be built and which should be borrowed.
AI & Digital Signals
Launch of Perceptic signals where AI in Life Sciences is heading
The launch of Perceptic by former Palantir executives offers a useful glimpse into where AI investment is heading.
The first phase of AI adoption in life sciences was dominated by models. Companies competed to develop better prediction engines, more powerful discovery platforms, and increasingly sophisticated foundation models. The assumption was that competitive advantage would come primarily from the technology itself.
That assumption is beginning to weaken.
Perceptic’s focus is not on building another discovery engine. Instead, it sits at the operating layer, attempting to connect fragmented workflows, decisions, and processes across drug development. This reflects a broader shift already visible across the industry. As advanced models become more accessible, differentiation increasingly moves towards orchestration, governance, workflow integration, and decision-making.
In other words, the challenge is becoming organisational rather than technical.
Most life sciences organisations can now acquire AI capability. Far fewer have redesigned how work gets done. The companies creating lasting value from AI are unlikely to be those with access to the most powerful models. They are more likely to be the organisations capable of integrating those models into coherent operating systems.
Regulation & Market Access
Regulation becomes Commercial story
The transition of the first EUDAMED modules into mandatory use on 28 May may appear to be a regulatory story. In reality, it is increasingly a commercial one.
Many organisations continue to treat EUDAMED as a compliance requirement. The more useful interpretation is to view it as infrastructure. Shared infrastructure has a habit of exposing weaknesses that previously remained hidden. Fragmented product information, inconsistent ownership, disconnected processes, and weak governance become much harder to manage when information moves into a common operating environment.
The companies that navigate EUDAMED successfully will not necessarily be those with the largest regulatory functions. They will be those that have invested in information governance across regulatory, quality, supply chain, market access, and commercial teams.
Regulatory infrastructure is becoming commercial infrastructure.
The same principle appears in Sanofi’s priority review for venglustat in type 3 Gaucher disease. Unlike Lilly, Sanofi is not entering unfamiliar territory. It is extending an existing rare disease franchise into a more complex patient population. The specialist centres, physician relationships, and diagnostic pathways already exist. Commercial value creation becomes easier when the surrounding capability is already in place.
MedTech & Commercialisation
CE mark opens access, does not create adoption.
Cornerstone Robotics’ MDR CE Mark approval for its Sentire surgical robotics platform highlights one of the most persistent misconceptions in MedTech: approval and adoption are often treated as though they are the same thing.
They are not.
The CE Mark provides access to the market. It does not create demand within it.
The commercial challenge begins after approval. Hospitals require economic justification, surgeons require training, clinical teams require confidence, and health systems require evidence. The incumbents in robotic surgery benefit from ecosystems that have taken years to build. Their advantage is not simply technological. It sits in installed bases, service capability, training networks, and institutional familiarity.
Cornerstone has acquired the right to compete.
Whether it can build the capability to win is now the more important question.
What Leaders Should Watch?
The most interesting pattern this week is that capability creation is becoming more important precisely because capability acquisition is becoming easier.
Technology can be purchased. Market access can be licensed. Assets can be acquired. Regulatory approvals can be secured.
The organisations that outperform will increasingly be those that focus on the operating layer that sits underneath those transactions.
That is where competitive advantage is becoming concentrated.
Practitioner’s Lens
The stories that mattered this week were not really about vaccines, AI, China, rare disease, medical devices, or regulation.
They were about organisational capability.
Life sciences organisations have become extraordinarily sophisticated at acquiring things. Assets move faster. Technology is easier to access. Partnerships can provide capabilities that once required years to build internally. The transaction layer of the industry has become remarkably efficient.
The capability layer remains stubbornly difficult.
That distinction sits underneath many of the industry’s current transformation challenges. AI programmes struggle not because models are weak but because operating models remain unchanged. Market expansions disappoint because local capability was assumed rather than built. Acquisitions underperform because organisational integration receives less attention than the deal itself.
The companies that outperform over the next decade will not necessarily be those making the biggest moves. They will be the organisations that consistently convert acquisitions, partnerships, technologies, and approvals into repeatable capability.
The transaction creates the opportunity.
The operating model determines whether the opportunity becomes an advantage.
One Thing to Remember
Acquiring capability creates potential. Operating capability creates value.
